Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types.
Musoro JZ, Coens C, Sprangers MAG, Brandberg Y, Groenvold M, Flechtner HH, Cocks K, Velikova G, Dirven L, Greimel E, Singer S, Pogoda K, Gamper EM, Sodergren SC, Eggermont A, Koller M, Reijneveld JC, Taphoorn MJB, King MT, Bottomley A; EORTC Melanoma, Breast, Head and Neck, Genito-urinary, Gynecological, Gastro-intestinal, Brain, Lung and Quality of Life Groups. Musoro JZ, et al. Eur J Cancer. 2023 Jul;188:171-182. doi: 10.1016/j.ejca.2023.04.027. Epub 2023 May 7. Eur J Cancer. 2023. PMID: 37257278 Free article.
Single-arm studies involving patient-reported outcome data in oncology: a literature review on current practice.
Liu L, Choi J, Musoro JZ, Sauerbrei W, Amdal CD, Alanya A, Barbachano Y, Cappelleri JC, Falk RS, Fiero MH, Regnault A, Reijneveld JC, Sandin R, Thomassen D, Roychoudhury S, Goetghebeur E, le Cessie S; SISAQOL-IMI Work Package 3. Liu L, et al. Among authors: musoro jz. Lancet Oncol. 2023 May;24(5):e197-e206. doi: 10.1016/S1470-2045(23)00110-9. Lancet Oncol. 2023. PMID: 37142381 Review.
Corrigendum to "Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma - Interpretation guidance derived from two randomized EORTC trials" [Lung Cancer 167C (2022) 65-72].
Koller M, Musoro JZ, Tomaszewski K, Coens C, King MT, Sprangers MAG, Groenvold M, Cocks K, Velikova G, Flechtner HH, Bottomley A. Koller M, et al. Among authors: musoro jz. Lung Cancer. 2022 Sep;171:126. doi: 10.1016/j.lungcan.2022.05.006. Epub 2022 May 20. Lung Cancer. 2022. PMID: 35606221 Free article. No abstract available.
Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma - Interpretation guidance derived from two randomized EORTC trials.
Koller M, Musoro JZ, Tomaszewski K, Coens C, King MT, Sprangers MAG, Groenvold M, Cocks K, Velikova G, Flechtner HH, Bottomley A. Koller M, et al. Among authors: musoro jz. Lung Cancer. 2022 May;167:65-72. doi: 10.1016/j.lungcan.2022.03.018. Epub 2022 Mar 29. Lung Cancer. 2022. PMID: 35413526
Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IVB mycosis fungoides/Sézary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT).
Stadler R, Romero PO, Bagot M, Quaglino P, Guenova E, Jonak C, Papadavid E, Stranzenbach R, Sartori D, Musoro JZ, Falato C, Marreaud S, Scarisbrick JJ, Knobler R. Stadler R, et al. Among authors: musoro jz. Eur J Cancer. 2021 Oct;156 Suppl 1:S22-S23. doi: 10.1016/S0959-8049(21)00668-7. Eur J Cancer. 2021. PMID: 34649647 No abstract available.
Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials.
Gamper EM, Musoro JZ, Coens C, Stelmes JJ, Falato C, Groenvold M, Velikova G, Cocks K, Flechtner HH, King MT, Bottomley A; EORTC Genito-Urinary Tract Cancer Group and Quality of Life Groups. Gamper EM, et al. Among authors: musoro jz. BMC Cancer. 2021 Oct 7;21(1):1083. doi: 10.1186/s12885-021-08609-7. BMC Cancer. 2021. PMID: 34620124 Free PMC article.
Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.
Musoro JZ, Coens C, Greimel E, King MT, Sprangers MAG, Nordin A, van Dorst EBL, Groenvold M, Cocks K, Velikova G, Flechtner HH, Bottomley A; EORTC Gynecological and Quality of Life Groups. Musoro JZ, et al. Gynecol Oncol. 2020 Nov;159(2):515-521. doi: 10.1016/j.ygyno.2020.09.007. Epub 2020 Sep 21. Gynecol Oncol. 2020. PMID: 32972782 Free article.
Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy.
Musoro JZ, Sodergren SC, Coens C, Pochesci A, Terada M, King MT, Sprangers MAG, Groenvold M, Cocks K, Velikova G, Flechtner HH, Bottomley A; EORTC Quality of Life, Gastro-intestinal Groups. Musoro JZ, et al. Colorectal Dis. 2020 Dec;22(12):2278-2287. doi: 10.1111/codi.15295. Epub 2020 Aug 28. Colorectal Dis. 2020. PMID: 32767619 Free article.
Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 scores in patients with head and neck cancer.
Musoro JZ, Coens C, Singer S, Tribius S, Oosting SF, Groenvold M, Simon C, Machiels JP, Grégoire V, Velikova G, Cocks K, Sprangers MAG, King MT, Bottomley A; EORTC Head and Neck and Quality of Life Groups. Musoro JZ, et al. Head Neck. 2020 Nov;42(11):3141-3152. doi: 10.1002/hed.26363. Epub 2020 Jul 6. Head Neck. 2020. PMID: 32627261 Free article.
21 results